The Enhanced Man community has two hormone-related religions, and both are wrong. The first church preaches DHT suppression to save hair while quietly losing sex drive, mental clarity, and strength. The second demonizes estrogen as a feminizing poison while unknowingly destroying cardiovascular tissue, bone density, and libido. DHT and estrogen are both essential in the male body, operating in a dynamic balance. Optimizing that balance requires understanding what each does — and which interventions help versus harm.
DHT: the forgotten King of Androgens
DHT (dihydrotestosterone) is produced from testosterone via the 5-alpha reductase enzyme. It is 3-5x more potent at the androgen receptor than testosterone — the most powerful natural androgen in the body.
What DHT Does: Masculinization (drove external genitalia development in utero), libido and sexual function (DHT is the primary libido driver — not testosterone, which is why finasteride destroys libido), cognitive function (DHT receptors are dense in the prefrontal cortex and hippocampus), Type II fast-twitch muscle fiber performance, skin integrity, and beard growth.
Optimal DHT Levels: 30-80 ng/dL. Low DHT (<20 ng/dL): low libido, depression, cognitive dysfunction, reduced strength. High DHT (>100 ng/dL): may accelerate prostate growth and hair loss in susceptible individuals.
Estrogen in Men: Reframing the Narrative
Estrogen is produced via aromatase-mediated conversion of testosterone to estradiol. Its functions in men: bone density (estrogen is MORE important than testosterone for male bone density), cardiovascular protection (maintains arterial flexibility, reduces LDL oxidation), libido (neurologically, estrogen in the hypothalamus drives the motivational aspects of libido), cognitive function (neuroprotective, prevents Alzheimer’s risk), mood stability (modulates serotonin, dopamine, BDNF), and joint health.
Optimal Estradiol for Men: 20-40 pg/mL (sensitive assay). Below 20: cardiovascular risk, bone loss, cognitive issues, joint pain, libido destruction. Above 60-70: gynecomastia risk, libido paradoxically decreases (suppresses LH/FSH), fat deposition issues.
Aromatase Control
Primary drivers of high aromatase: high body fat (largest aromatase source), insulin resistance (high insulin upregulates aromatase), zinc deficiency (zinc inhibits aromatase — 15-30mg daily), and inflammation. Fixing these lifestyle factors is always the first intervention before pharmaceuticals.
When to Use Aromatase Inhibitors
AI criteria: estradiol consistently above 50-60 pg/mL with symptoms (confirmed by two labs on sensitive assay), lifestyle optimization already addressed, and estrogen elevation is secondary to hormone optimization. Protocol: Anastrozole 0.25mg twice weekly as a starting point. Retest in 6-8 weeks. The goal is to optimize to 20-40 pg/mL — not to minimize estrogen.
DHT: The Honest Trade-Off
5-alpha reductase inhibitors (finasteride, dutasteride) suppress DHT by 60-90%, effectively slowing androgenic alopecia. The cost: libido reduction, erectile dysfunction (persistently in 1-10% of users), depression, anxiety, cognitive impairment, reduced strength. Post-Finasteride Syndrome is a documented condition where side effects persist indefinitely after stopping, affecting 1-3% of users. What is not acceptable is starting finasteride without fully understanding this trade-off — which dermatologists rarely disclose adequately.
Supporting DHT Naturally
Optimize testosterone first (Testosterone Optimization Protocol). Creatine 5g daily (increases 5AR enzyme activity and DHT by approximately 56% in one well-designed trial). Optimal body fat. Zinc and selenium support 5AR function.
The Hormone Balance Stack
Test total T, free T, E2 (sensitive), DHT, SHBG, LH, FSH every 8-12 weeks when adjusting. Targets: Total T 700-1000+ ng/dL, E2 20-40 pg/mL, DHT 40-80 ng/dL. Use lifestyle interventions first. Use AIs only when lifestyle optimization is insufficient. Never use AIs to crush estrogen — always dose to the optimal range. Start with the Enhanced Athlete Protocol hub and track bloodwork at Enhanced Athlete Bloodwork.
Interesting Perspectives
The conventional view of DHT and estrogen as simple antagonists is outdated. Emerging perspectives suggest their interplay is more synergistic and context-dependent. Some biohackers are exploring the concept of “estrogen priming” for neuroprotection and cardiovascular health before aggressive androgen cycles, arguing that a temporary, controlled elevation in estradiol can upregulate protective pathways. Conversely, the role of DHT in metabolic health is being re-examined; low DHT is correlated with insulin resistance and poor lipid profiles, suggesting its suppression may have systemic metabolic costs beyond sexual function. The Tony Huge Laws of Biochemistry Physics dictate that receptor saturation and feedback loops create non-linear responses; crushing one hormone to fix a perceived problem (like hair loss or high E2) often creates a cascade of unintended deficits elsewhere in the system. The goal isn’t to win a battle between DHT and estrogen, but to orchestrate their concert.
Related Video: The Exact Hormone Strategy I Use to Upgrade My Physique and Face
Related Video: Why High Estrogen Might Be the Secret to Faster Muscle Growth
Citations & References
- Traish, A. M. (2018). The Post-Finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Current Sexual Health Reports.
- Finkelstein, J. S., et al. (2013). Gonadal steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine.
- Rochira, V., & Carani, C. (2009). Aromatase deficiency in men: a clinical perspective. Nature Reviews Endocrinology.
- van den Beld, A. W., et al. (2000). Measures of Bioavailable Serum Testosterone and Estradiol and Their Relationships with Muscle Strength, Bone Density, and Body Composition in Elderly Men. The Journal of Clinical Endocrinology & Metabolism.
- Giltay, E. J., et al. (2012). Salivary testosterone: associations with depression, anxiety disorders, and antidepressant use in a large cohort study. Journal of Psychosomatic Research.
- Kaufman, J. M., & Vermeulen, A. (2005). The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine Reviews.